The United States still leads China in biotechnology, but that lead is narrowing and could vanish by 2030, according to the latest Biotech Scorecard from the Special Competitive Studies Project (SCSP), a nonprofit and nonpartisan initiative aimed at strengthening America's long-term competitiveness in artificial intelligence. The findings matter because biotechnology leadership underpins not only public health but also economic competitiveness, national security, and supply chain resilience.
SCSP's Tech Scorecard methodology evaluates five elements: Innovation Leadership, Market Ecosystem, Talent Pipeline, Industrial Capacity, and National Leverage. The United States holds the advantage in Innovation Leadership, Market Ecosystem, and Talent Pipeline, while China appears ahead in Industrial Capacity and National Leverage, according to the report. That split is significant: it suggests the U.S. edge rests on past strengths, while China's position is being actively built for the future.
China has the potential to overtake the U.S. in biotechnology by 2030, strengthened by two decades of deliberate national strategy now producing results. By contrast, the American position is "a return on research investments made decades ago, sustained by a capital market that rewards its strongest performers," according to SCSP's analysts. The report focuses on the biopharmaceuticals sector to illustrate China's acceleration in National Leverage and Industrial Capacity.
Most U.S. government funding for biotechnology goes to basic research. A lack of urgency persists in expanding government support for the commercialization of drug products, for example. "Approval timelines for drugs entering clinical trials and going to domestic markets are driven by government policy, and can help accelerate, or slow down, the pipeline of innovation," the SCSP authors emphasize. The implication is that regulatory speed and commercial support are now competitive variables, not administrative details.
Although both countries invest in basic research, China is more active in supporting biotech startups through the process of acquiring capital to build pilot capacity, scale up production, and reach markets, without waiting for a definitive return on these expanded investments. This strategy includes preferential taxation, below-market lending, and direct subsidies. The U.S. tends to leave this aspect of biotechnology development to the private sector, which may leave gaps in scaling and manufacturing capacity that China is filling.
Looking ahead, as artificial intelligence allows scientists to predict molecular activity, the expensive early stages of drug discovery will likely decrease, and the competitive advantage will shift to testing, manufacturing, and commercializing a promising drug candidate. "Whether the United States retains its edge depends both on model quality and how quickly it can move a computationally generated candidate through trials, approval, and manufacture before a competitor improves on it," according to the report. That shift raises the stakes for U.S. policy on manufacturing, regulation, and commercialization support.
The full report is available through scsp.ai, and the announcement was distributed via (NewsUSA).
